ProMACE-cytaBOM versus MACOP-B in intermediate and high grade NHL. Preliminary results of a prospective randomized trial.

abstract：:Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to 12/2014, Nordic and Baltic centers treated 1509 consecutive patients aged 1-45 years with Philadelphia chromosome-negative ALL according to the NOPHO ALL2008 without cranial irradiation. Overall, 1022 patients were of age 1-9 years (...

journal_title：Leukemia

authors： Toft N,Birgens H,Abrahamsson J,Griškevičius L,Hallböök H,Heyman M,Klausen TW,Jónsson ÓG,Palk K,Pruunsild K,Quist-Paulsen P,Vaitkeviciene G,Vettenranta K,Åsberg A,Frandsen TL,Marquart HV,Madsen HO,Norén-Nyström U,Schmi

更新日期：2018-03-01 00:00:00

abstract：:Philadelphia (Ph) chromosome or the bcr/abl fusion gene is the hallmark of chronic myeloid leukemia (CML) and serves as a prognostic marker during its treatment. Its detection has been primarily done by karyotype analysis of bone marrow cells. The major limitation of the karyotypic technique is an absolute need for me...

journal_title：Leukemia

authors： Yanagi M,Shinjo K,Takeshita A,Tobita T,Yano K,Kobayashi M,Terasaki H,Naoe T,Ohnishi K,Ohno R

更新日期：1999-04-01 00:00:00

abstract：:Only two classes of chemotherapeutic agents have shown activity in acute myeloid leukemia (AML): ara-C and topoisomerase II reactive agents. Frontline combinations of these agents produce complete response (CR) rates of 70% and long-term event free survival rates of 25%. New agents with different mechanisms of action ...

journal_title：Leukemia

authors： Kantarjian HM,Estey EH,Keating MA

更新日期：1996-04-01 00:00:00

abstract：:Signal transducer and activator of transcription (Stat)3 is constitutively activated in cutaneous T-cell lymphoma (CTCL), where it protects tumour cells against apoptosis. The constitutive activation of Stat3 leads to a constitutive expression of suppressor of cytokine signalling (SOCS)-3. In healthy cells, SOCS-3 is ...

journal_title：Leukemia

authors： Brender C,Lovato P,Sommer VH,Woetmann A,Mathiesen AM,Geisler C,Wasik M,Ødum N

更新日期：2005-02-01 00:00:00

abstract：:The T-lineage phenotype in children with acute lymphoblastic leukaemia (ALL) is associated with in vitro drug resistance and a higher relapse-risk compared to a precursor B phenotype. Our study was aimed to investigate whether mutations in the ATM gene occur in childhood T-lineage acute lymphoblastic leukaemia (T-ALL)...

journal_title：Leukemia

authors： Meier M,den Boer ML,Hall AG,Irving JA,Passier M,Minto L,van Wering ER,Janka-Schaub GE,Pieters R

更新日期：2005-11-01 00:00:00

abstract：:Spliceosome mutations represent a new generation of acquired genetic alterations that affect both myeloid and lymphoid malignancies. A substantial proportion of patients with myelodysplastic syndromes (MDSs) or chronic lymphocytic leukemia (CLL) harbor such mutations, which are often missense in type. Genotype-phenoty...

journal_title：Leukemia

authors： Damm F,Nguyen-Khac F,Fontenay M,Bernard OA

更新日期：2012-09-01 00:00:00

abstract：:The immune response to leukemia is poorly understood. We postulated that nonmalignant T lymphocytes remaining within bone marrow from children with newly diagnosed ALL could be involved in this immune response. T lymphocytes which expressed gamma delta TCR comprised less than 1% of ALL marrow cells. A preferential out...

journal_title：Leukemia

authors： Duval M,Yotnda P,Bensussan A,Oudhiri N,Guidal C,Rohrlich P,Boumsell L,Grandchamp B,Vilmer E

更新日期：1995-05-01 00:00:00

abstract：:The microenvironments of leukemia and cancer are critical for multiple stages of malignancies, and they are an attractive therapeutic target. While skeletal abnormalities are commonly seen in children with acute lymphoblastic leukemia (ALL) prior to initiating osteotoxic therapy, little is known about the alterations ...

journal_title：Leukemia

authors： Cheung LC,Tickner J,Hughes AM,Skut P,Howlett M,Foley B,Oommen J,Wells JE,He B,Singh S,Chua GA,Ford J,Mullighan CG,Kotecha RS,Kees UR

更新日期：2018-11-01 00:00:00

abstract：:Adult BL/6 mice are highly sensitive to lymphomagnesis by the radiation leukemia virus variant A-RadLV (80-100% T-cell lymphoma incidence after a latency of 70-110 days). This study shows that the in vivo elimination of T-cell subsets (including suppressor and cytotoxic T-cells) achieved by the repeated administration...

journal_title：Leukemia

authors： Haran-Ghera N,Peled A

更新日期：1991-06-01 00:00:00

abstract：:The inhibition of nuclear factor kappa B (NF-kappaB) by, for instance, curcumin is becoming an important new approach in combination with chemotherapy or irradiation for the treatment of a variety of cancers including haematological malignancies. A dose-limiting side effect of anticancer therapy in the gastrointestina...

journal_title：Leukemia

authors： van't Land B,Blijlevens NM,Marteijn J,Timal S,Donnelly JP,de Witte TJ,M'Rabet L

更新日期：2004-02-01 00:00:00

abstract：:Real-time quantitative polymerase chain reaction (PCR) for BCR-ABL mRNA in the peripheral blood (RQ-PCR) provides an accurate and reliable measure of response to therapy in chronic myeloid leukaemia (CML). We wanted to determine in what circumstances additional clinically relevant information was provided by simultane...

journal_title：Leukemia

authors： Ross DM,Branford S,Moore S,Hughes TP

更新日期：2006-04-01 00:00:00

abstract：:HOX homeobox proteins are key oncogenic drivers in hematopoietic malignancies. Here we demonstrate that HOXA1, HOXA6 and predominantly HOXA9 are able to induce the production of insulin-like growth factor 1 (Igf1). In chromatin immunoprecipitations, HOXA9 bound directly to the putative promoter and a DNase-hypersensit...

journal_title：Leukemia

authors： Steger J,Füller E,Garcia-Cuellar MP,Hetzner K,Slany RK

更新日期：2015-04-01 00:00:00

abstract：:Cell lines of myeloid origin have been shown to express interleukin-2 receptors (IL-2R). Here, we demonstrate the expression of IL-2R alpha and IL-R beta on the CML blast cell line K562 by FACS analysis and cross-linking assay. Furthermore, we examined the effect of IL-2 on leukemic progenitor growth, employing K562 a...

journal_title：Leukemia

authors： Dilloo D,Hanenberg H,Lion T,Burdach S

更新日期：1995-03-01 00:00:00

abstract：:Anaplastic large cell lymphoma (ALCL) expressing the CD30 antigen is an uncommon subtype of non-Hodgkin's lymphoma characterized by distinct morphological and clinical features. The recurrent chromosomal abnormality found in these tumours is a t(2;5)(p23;q35) which has been detected in a minority of these cases, predo...

journal_title：Leukemia

authors： Wlodarska I,De Wolf-Peeters C,Michaux L,Mecucci C,Verhoef G,Cassiman JJ,Van den Berghe H

更新日期：1995-10-01 00:00:00

abstract：:Conditionally replicating adenoviruses (CRAds) represent a promising new platform for anticancer therapy. However, CRAds have been evaluated little in hematopoietic malignancies because of the lack of expression of coxsackie adenovirus receptor (CAR) on their cell surface. In this study, we showed that CAR was express...

journal_title：Leukemia

authors： Qian W,Liu J,Tong Y,Yan S,Yang C,Yang M,Liu X

更新日期：2008-02-01 00:00:00

abstract：:We have previously shown that chronic lymphocytic leukemia (CLL) B cells secrete vascular endothelial growth factor (VEGF) in vitro, have constitutively active VEGF receptors R1 and R2, and respond to exogenous VEGF by specifically upregulating Mcl-1 and XIAP in association with decreased cell death. We found that epi...

journal_title：Leukemia

authors： Lee YK,Shanafelt TD,Bone ND,Strege AK,Jelinek DF,Kay NE

更新日期：2005-04-01 00:00:00

abstract：:We analyzed the long-term outcome of 1011 patients treated in five successive clinical trials (Total Therapy Studies 11, 12, 13A, 13B, and 14) between 1984 and 1999. The event-free survival improved significantly (P=0.003) from the first two trials conducted in the 1980s to the three more recent trials conducted in th...

journal_title：Leukemia

authors： Pui CH,Pei D,Sandlund JT,Ribeiro RC,Rubnitz JE,Raimondi SC,Onciu M,Campana D,Kun LE,Jeha S,Cheng C,Howard SC,Metzger ML,Bhojwani D,Downing JR,Evans WE,Relling MV

更新日期：2010-02-01 00:00:00

abstract：:Since in vitro observations indicated that all-trans retinoic acid (ATRA), especially in combination with IFNalpha, can exert significant suppressive effects on Ph+ cells, we investigated the effects and the pharmacokinetic profile of ATRA in a selected cohort of patients with Ph+ chronic myeloid leukemia (CML) in chr...

journal_title：Leukemia

authors： Russo D,Regazzi M,Sacchi S,Visani G,Lazzarino M,Avvisati G,Pelicci PG,Dastoli G,Grandi C,Iacona I,Candoni A,Grattoni R,Galieni P,Rupoli S,Liberati AM,Maiolo AT

更新日期：1998-04-01 00:00:00

abstract：:Myeloproliferative neoplasms with myelofibrosis (MPN-MF) demonstrate constitutive activation of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling that responds to treatment with the JAK1 and 2 kinase inhibitor (JAKi) ruxolitinib. However, MPN-MF often progresses (~20%) to secondary acu...

journal_title：Leukemia

authors： Saenz DT,Fiskus W,Manshouri T,Rajapakshe K,Krieger S,Sun B,Mill CP,DiNardo C,Pemmaraju N,Kadia T,Parmar S,Sharma S,Coarfa C,Qiu P,Verstovsek S,Bhalla KN

更新日期：2017-03-01 00:00:00

abstract：:T-cell large granular lymphocytic (LGL) leukemia is a complex diagnosis, requiring persistent clonal expansions of LGLs, and cytopenias. Often the diagnosis is unclear as non-clonal expansions of LGLs commonly occur in reactive conditions. To better understand T-LGL leukemia, we performed a comprehensive clinicopathol...

journal_title：Leukemia

authors： Ohgami RS,Ohgami JK,Pereira IT,Gitana G,Zehnder JL,Arber DA

更新日期：2011-09-01 00:00:00

abstract：:Targeted therapies are frequently combined with standard cytotoxic drugs to enhance clinical response. Targeting the B-cell lymphoma 2 (BCL-2) family of proteins is an attractive option to combat chemoresistance in leukemia. Preclinical and clinical studies indicate modest single-agent activity with selective BCL-2 in...

journal_title：Leukemia

authors： Teh TC,Nguyen NY,Moujalled DM,Segal D,Pomilio G,Rijal S,Jabbour A,Cummins K,Lackovic K,Blombery P,Thompson E,Ekert PG,Lessene G,Glaser SP,Huang DCS,Roberts AW,Guthridge MA,Wei AH

更新日期：2018-02-01 00:00:00

abstract：:Chimeric antigen receptor (CAR) T cell therapies lead to high clinical response rates in B cell malignancies, and are under investigation for treatment of solid tumors. While high systemic interleukin- (IL-) 6 levels are associated with clinical cytokine release syndrome (CRS), the role of IL-6 trans-signaling within ...

journal_title：Leukemia

authors： Jiang Z,Liao R,Lv J,Li S,Zheng D,Qin L,Wu D,Chen S,Long Y,Wu Q,Wang S,Lin S,Huang X,Tang Z,Shi P,Zhou H,Liu Q,Zhao R,Li Y,Jie Y,Wei W,Lai P,Du X,Cui S,Weinkove R,Liu P,Pei D,Yao Y,Li P

更新日期：2020-11-09 00:00:00

abstract：:Osteopontin (OPN) is a multifunctional bone matrix glycoprotein that is involved in angiogenesis, cell survival and tumor progression. In this study we show that human myeloma cells directly produce OPN and express its major regulating gene Runx2/Cbfa1. The activity of Runx2/Cbfa1 protein in human myeloma cells has al...

journal_title：Leukemia

authors： Colla S,Morandi F,Lazzaretti M,Rizzato R,Lunghi P,Bonomini S,Mancini C,Pedrazzoni M,Crugnola M,Rizzoli V,Giuliani N

更新日期：2005-12-01 00:00:00

abstract：:An increasing number of variants of unknown significance are being identified in leukemia patients with the application of deep sequencing and these include CSF3R cytoplasmic mutations. Previous studies have demonstrated oncogenic potential of certain CSF3R truncation mutations prior to internalization motifs. However...

journal_title：Leukemia

authors： Zhang H,Reister Schultz A,Luty S,Rofelty A,Su Y,Means S,Bottomly D,Wilmot B,McWeeney SK,Tyner JW

更新日期：2017-12-01 00:00:00

abstract：:The number of allogeneic transplants from unrelated donors has grown in the past decade in part because of the expansion of the donor registry size. Patient survival has improved due to the selection of more closely matched donors and the development of effective infection prophylaxis. Relapse-free survival remains li...

journal_title：Leukemia

authors： Anasetti C

更新日期：2000-03-01 00:00:00

abstract：:Unlike the case with acute myeloid leukemia, there is limited information on the prognostic impact of isocitrate dehydrogenase (IDH) mutations in myelodysplastic syndromes (MDS). In the current study of 277 patients with MDS, IDH mutations were detected in 34 (12%) cases: 26 IDH2 (all R140Q) and 8 IDH1 (6 R132S and 2 ...

journal_title：Leukemia

authors： Patnaik MM,Hanson CA,Hodnefield JM,Lasho TL,Finke CM,Knudson RA,Ketterling RP,Pardanani A,Tefferi A

更新日期：2012-01-01 00:00:00

abstract：:The efficacy of antibody-based immunotherapy is due to the activation of apoptosis, the engagement of antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity (CDC). We developed a novel strategy to enhance CDC using bispecific antibodies (bsAbs) that neutralize the C-regulators CD55 and CD59 to ...

journal_title：Leukemia

authors： Macor P,Secco E,Mezzaroba N,Zorzet S,Durigutto P,Gaiotto T,De Maso L,Biffi S,Garrovo C,Capolla S,Tripodo C,Gattei V,Marzari R,Tedesco F,Sblattero D

更新日期：2015-02-01 00:00:00

abstract：:Malignant cells of patients with cutaneous T cell lymphoma (CTCL) are of monoclonal origin and of the CD4+/CD45RO+ subset. Since unlike their normal counterparts, triggering of their TCR/CD3 in vitro elicits only a weak mitogenic response, we set out to determine which of the signal transduction molecules initiated by...

journal_title：Leukemia

authors： Fargnoli MC,Edelson RL,Berger CL,Chimenti S,Couture C,Mustelin T,Halaban R

更新日期：1997-08-01 00:00:00

abstract：:We studied the differentiation profiles of B cell precursors (BCP) in normal and post-chemotherapy pediatric bone marrow (BM) using multiparameter flow cytometry. The goal of our study was to draw a comprehensive phenotypic map of the three major maturational BCP stages in BM. By correlating lineage-associated markers...

journal_title：Leukemia

authors： Dworzak MN,Fritsch G,Fleischer C,Printz D,Fröschl G,Buchinger P,Mann G,Gadner H

更新日期：1997-08-01 00:00:00

abstract：:In this open-label randomized clinical trial, HLA-identical sibling-matched hematopoietic stem cells (HSC) were transplanted (non-MSCs group, n=15) or cotransplanted with mesenchymal stem cells (MSCs) (MSCs group, n=10) in hematologic malignancy patients. The median number of MSCs infused was 3.4 x 10(5) kg(-1) (range...

journal_title：Leukemia

authors： Ning H,Yang F,Jiang M,Hu L,Feng K,Zhang J,Yu Z,Li B,Xu C,Li Y,Wang J,Hu J,Lou X,Chen H

更新日期：2008-03-01 00:00:00